Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.

ABSTRACT:

Importance

It is uncertain whether lipoprotein(a) [Lp(a)], which is associated with incident cardiovascular disease, is an independent risk factor for recurrent cardiovascular events after acute coronary syndrome (ACS).

Objective

To determine the association of Lp(a) concentration measured after ACS with the subsequent risk of ischemic cardiovascular events.

Design, setting, and participants

This nested case-cohort analysis was performed as an ad hoc analysis of the dal-Outcomes randomized clinical trial. This trial compared dalcetrapib, the cholesteryl ester transfer protein inhibitor, with placebo in patients with recent ACS and was performed between April 2008 and September 2012 at 935 sites in 27 countries. There were 969 case patients who experienced a primary ca

SUBMITTER: Schwartz GG 

PROVIDER: S-EPMC5838593 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature